Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05047978 · ClinicalTrials.gov registry record · NA
Growth and Tolerance of a Partially Hydrolyzed Infant Formula
A NA study, sponsored by Mead Johnson Nutrition.
- Completed
- Registry status
- NA
- Development phase
- 244
- Enrollment target
NCT05047978: Completed NA study, sponsored by Mead Johnson Nutrition.
NCT05047978 is a NA study that has completed, run by Mead Johnson Nutrition. The registered enrollment target is 244 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05047978, a NA study, has completed, sponsored by Mead Johnson Nutrition.
- COMPLETED
- Registry status
- NA
- Development phase
- 244 participants
- Enrollment target
Study Summary
The purpose of this research study is to compare the growth and tolerance of infants who consume either an infant formula with intact proteins or an infant formula with partially hydrolyzed proteins through approximately 12 months of age.
Interventions
- OTHER Cow's milk protein infant formula
- OTHER Partially hydrolyzed protein infant formula
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 244 participants |
| Start Date | 2021-08-28 |
| Est. Completion | 2023-11-21 |
| Phase | NA |
What the finished NCT05047978 record still lists
NCT05047978 is an interventional study that assigns participants to a tested intervention. The registered 244 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 2 interventions - of which Cow's milk protein infant formula is the first listed.
NCT05047978 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05047978 about?
NCT05047978 is a clinical study titled "Growth and Tolerance of a Partially Hydrolyzed Infant Formula". The purpose of this research study is to compare the growth and tolerance of infants who consume either an infant formula with intact proteins or an infant formula with partially hydrolyzed proteins through approximately 12 months of age.
What is the current status of trial NCT05047978?
This trial is currently completed. It is a NA study. The enrollment target is 244 participants. The study started on 2021-08-28. Estimated completion is 2023-11-21.
What interventions are being tested in trial NCT05047978?
The interventions under investigation include: Cow's milk protein infant formula (OTHER), Partially hydrolyzed protein infant formula (OTHER).
Who is sponsoring clinical trial NCT05047978?
This trial is sponsored by Mead Johnson Nutrition, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05047978's enrollment target sits among peer trials
244 438th of 2000 higher than 1,563 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02227251 · 244 participants · Phase 2
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- NCT04317534 · 244 participants · Phase 2
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
- NCT04683250 · 244 participants · Phase 1
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
- NCT04686305 · 244 participants · Phase 1
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI